Elizabeth Mittendorf, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 247 | 2024 | 20840 | 10.570 |
Why?
|
| Cancer Vaccines | 43 | 2023 | 1048 | 7.000 |
Why?
|
| Sentinel Lymph Node Biopsy | 58 | 2023 | 720 | 6.820 |
Why?
|
| Receptor, erbB-2 | 75 | 2024 | 2483 | 6.730 |
Why?
|
| Neoadjuvant Therapy | 88 | 2024 | 2789 | 6.530 |
Why?
|
| Lymph Node Excision | 49 | 2024 | 1290 | 3.980 |
Why?
|
| Mastectomy, Segmental | 23 | 2024 | 957 | 3.910 |
Why?
|
| Axilla | 52 | 2024 | 612 | 3.900 |
Why?
|
| Neoplasm Staging | 90 | 2024 | 11063 | 3.540 |
Why?
|
| Carcinoma, Ductal, Breast | 32 | 2020 | 1085 | 3.290 |
Why?
|
| Neoplasm Recurrence, Local | 60 | 2024 | 9207 | 3.280 |
Why?
|
| Lymph Nodes | 39 | 2023 | 3474 | 3.150 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 17 | 2024 | 932 | 2.870 |
Why?
|
| Mastectomy | 35 | 2023 | 1822 | 2.670 |
Why?
|
| Carcinoma, Lobular | 18 | 2020 | 490 | 2.650 |
Why?
|
| Receptors, Estrogen | 36 | 2024 | 2181 | 2.520 |
Why?
|
| Vaccines, Subunit | 15 | 2023 | 163 | 2.430 |
Why?
|
| Peptide Fragments | 24 | 2023 | 5070 | 2.080 |
Why?
|
| Immunotherapy | 32 | 2024 | 4601 | 2.060 |
Why?
|
| Lymphatic Metastasis | 53 | 2023 | 2924 | 2.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 53 | 2024 | 11587 | 1.960 |
Why?
|
| Chemotherapy, Adjuvant | 47 | 2024 | 3489 | 1.640 |
Why?
|
| Receptors, Progesterone | 22 | 2021 | 1114 | 1.490 |
Why?
|
| Prognosis | 71 | 2024 | 29337 | 1.440 |
Why?
|
| Female | 277 | 2024 | 386085 | 1.330 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 13 | 2023 | 882 | 1.310 |
Why?
|
| HLA-A2 Antigen | 10 | 2023 | 211 | 1.270 |
Why?
|
| Neoplasm, Residual | 11 | 2022 | 994 | 1.270 |
Why?
|
| T-Lymphocytes, Cytotoxic | 15 | 2020 | 1758 | 1.230 |
Why?
|
| Leukocyte Elastase | 5 | 2017 | 114 | 1.230 |
Why?
|
| Humans | 328 | 2024 | 752411 | 1.090 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 11 | 2022 | 1060 | 1.030 |
Why?
|
| Paclitaxel | 11 | 2024 | 1699 | 0.950 |
Why?
|
| Antigens, Neoplasm | 11 | 2023 | 1989 | 0.910 |
Why?
|
| Inflammatory Breast Neoplasms | 3 | 2024 | 144 | 0.900 |
Why?
|
| Disease-Free Survival | 24 | 2021 | 6780 | 0.900 |
Why?
|
| CD8-Positive T-Lymphocytes | 11 | 2020 | 4495 | 0.840 |
Why?
|
| Neoplastic Cells, Circulating | 5 | 2019 | 935 | 0.820 |
Why?
|
| Aged | 123 | 2024 | 166585 | 0.810 |
Why?
|
| Survival Rate | 34 | 2021 | 12745 | 0.800 |
Why?
|
| Middle Aged | 142 | 2024 | 217039 | 0.740 |
Why?
|
| Tumor Microenvironment | 15 | 2024 | 3755 | 0.730 |
Why?
|
| Biological Factors | 2 | 2020 | 157 | 0.730 |
Why?
|
| Lymphedema | 6 | 2024 | 525 | 0.730 |
Why?
|
| SEER Program | 4 | 2024 | 1516 | 0.700 |
Why?
|
| Cytotoxicity, Immunologic | 5 | 2020 | 1337 | 0.680 |
Why?
|
| Adult | 126 | 2024 | 216927 | 0.650 |
Why?
|
| Aged, 80 and over | 62 | 2024 | 58299 | 0.650 |
Why?
|
| Parathyroidectomy | 4 | 2007 | 240 | 0.640 |
Why?
|
| Folate Receptors, GPI-Anchored | 1 | 2018 | 23 | 0.630 |
Why?
|
| Tamoxifen | 4 | 2024 | 960 | 0.630 |
Why?
|
| Neoplasm Invasiveness | 17 | 2020 | 3585 | 0.620 |
Why?
|
| Antineoplastic Agents | 17 | 2024 | 13550 | 0.610 |
Why?
|
| Thyroidectomy | 6 | 2008 | 896 | 0.600 |
Why?
|
| Follow-Up Studies | 50 | 2024 | 39077 | 0.600 |
Why?
|
| Albumins | 1 | 2020 | 565 | 0.600 |
Why?
|
| Combined Modality Therapy | 21 | 2024 | 8539 | 0.580 |
Why?
|
| Breast | 12 | 2024 | 1975 | 0.580 |
Why?
|
| Nomograms | 4 | 2016 | 238 | 0.570 |
Why?
|
| Continuity of Patient Care | 1 | 2024 | 1050 | 0.560 |
Why?
|
| Prospective Studies | 48 | 2024 | 53809 | 0.530 |
Why?
|
| Estrogen Receptor alpha | 2 | 2019 | 577 | 0.520 |
Why?
|
| Antigen Presentation | 6 | 2023 | 1237 | 0.510 |
Why?
|
| Hyperparathyroidism | 4 | 2007 | 337 | 0.510 |
Why?
|
| Testicular Neoplasms | 1 | 2021 | 795 | 0.510 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2020 | 1519 | 0.500 |
Why?
|
| Dendritic Cells | 7 | 2019 | 2715 | 0.500 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2019 | 820 | 0.490 |
Why?
|
| Ferrosoferric Oxide | 1 | 2016 | 348 | 0.480 |
Why?
|
| Vaccination | 9 | 2018 | 3322 | 0.480 |
Why?
|
| Neoplasms | 13 | 2022 | 21806 | 0.460 |
Why?
|
| Dextrans | 1 | 2016 | 571 | 0.460 |
Why?
|
| Radiotherapy | 2 | 2020 | 1506 | 0.460 |
Why?
|
| Ovarian Neoplasms | 4 | 2019 | 4808 | 0.440 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 3 | 2022 | 5208 | 0.430 |
Why?
|
| Patient Preference | 1 | 2020 | 904 | 0.430 |
Why?
|
| Hypocalcemia | 3 | 2004 | 196 | 0.430 |
Why?
|
| Antibodies, Monoclonal | 13 | 2024 | 9101 | 0.430 |
Why?
|
| Treatment Outcome | 47 | 2024 | 64250 | 0.410 |
Why?
|
| Pathology, Clinical | 1 | 2016 | 367 | 0.410 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2008 | 732 | 0.400 |
Why?
|
| Adjuvants, Immunologic | 6 | 2016 | 1024 | 0.390 |
Why?
|
| Observer Variation | 2 | 2016 | 2583 | 0.390 |
Why?
|
| Mast Cells | 1 | 2019 | 1432 | 0.390 |
Why?
|
| Health Plan Implementation | 1 | 2014 | 332 | 0.380 |
Why?
|
| Cell Line, Tumor | 20 | 2023 | 16737 | 0.370 |
Why?
|
| Biology | 2 | 2024 | 289 | 0.360 |
Why?
|
| Adenocarcinoma | 5 | 2011 | 6304 | 0.360 |
Why?
|
| Histocompatibility Antigens Class II | 2 | 2019 | 1415 | 0.360 |
Why?
|
| GPI-Linked Proteins | 1 | 2012 | 465 | 0.360 |
Why?
|
| Histocompatibility Antigens Class I | 2 | 2016 | 1323 | 0.360 |
Why?
|
| Retrospective Studies | 44 | 2024 | 79133 | 0.350 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2020 | 1417 | 0.350 |
Why?
|
| Thyroid Neoplasms | 5 | 2022 | 2309 | 0.350 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2011 | 626 | 0.350 |
Why?
|
| Peptides | 6 | 2024 | 4292 | 0.350 |
Why?
|
| Ketones | 2 | 2021 | 181 | 0.350 |
Why?
|
| Furans | 2 | 2021 | 193 | 0.350 |
Why?
|
| Cyclin E | 1 | 2010 | 157 | 0.340 |
Why?
|
| Taxoids | 6 | 2023 | 664 | 0.330 |
Why?
|
| Genes, erbB-2 | 2 | 2010 | 162 | 0.330 |
Why?
|
| Gene Expression Profiling | 6 | 2021 | 9356 | 0.330 |
Why?
|
| Mastectomy, Simple | 3 | 2017 | 23 | 0.320 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2009 | 316 | 0.310 |
Why?
|
| Cross-Priming | 4 | 2018 | 76 | 0.310 |
Why?
|
| Decision Making | 7 | 2024 | 3888 | 0.310 |
Why?
|
| Lung Neoplasms | 5 | 2022 | 13167 | 0.310 |
Why?
|
| Cathepsin G | 3 | 2022 | 31 | 0.300 |
Why?
|
| Biopsy, Needle | 5 | 2018 | 1632 | 0.300 |
Why?
|
| Rosaniline Dyes | 3 | 2019 | 48 | 0.300 |
Why?
|
| Young Adult | 35 | 2022 | 57632 | 0.300 |
Why?
|
| False Negative Reactions | 6 | 2017 | 572 | 0.290 |
Why?
|
| Drug Discovery | 1 | 2015 | 1056 | 0.290 |
Why?
|
| Clinical Trials as Topic | 12 | 2024 | 7996 | 0.290 |
Why?
|
| Single-Blind Method | 4 | 2020 | 1573 | 0.290 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2021 | 8422 | 0.290 |
Why?
|
| Parathyroid Neoplasms | 2 | 2007 | 241 | 0.290 |
Why?
|
| Carcinoma, Islet Cell | 1 | 2006 | 21 | 0.280 |
Why?
|
| Radiotherapy, Adjuvant | 8 | 2024 | 1774 | 0.270 |
Why?
|
| Societies, Medical | 6 | 2021 | 3834 | 0.270 |
Why?
|
| Survival Analysis | 14 | 2021 | 10172 | 0.270 |
Why?
|
| Magnetite Nanoparticles | 2 | 2019 | 316 | 0.260 |
Why?
|
| HLA-A3 Antigen | 4 | 2014 | 34 | 0.260 |
Why?
|
| Tumor Escape | 2 | 2020 | 367 | 0.260 |
Why?
|
| Sternum | 2 | 2019 | 175 | 0.260 |
Why?
|
| Electronic Health Records | 1 | 2022 | 4632 | 0.250 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2024 | 6501 | 0.250 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2005 | 323 | 0.250 |
Why?
|
| Lithiasis | 1 | 2005 | 19 | 0.250 |
Why?
|
| Cecal Diseases | 1 | 2005 | 49 | 0.250 |
Why?
|
| Neoplasm Metastasis | 9 | 2021 | 4862 | 0.250 |
Why?
|
| Pheochromocytoma | 1 | 2007 | 326 | 0.250 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2007 | 162 | 0.240 |
Why?
|
| Cyclophosphamide | 4 | 2022 | 2194 | 0.240 |
Why?
|
| Rectus Abdominis | 1 | 2005 | 103 | 0.240 |
Why?
|
| Pancreatic Neoplasms | 4 | 2020 | 5288 | 0.240 |
Why?
|
| Hematologic Neoplasms | 1 | 2016 | 1864 | 0.240 |
Why?
|
| Biliary Fistula | 1 | 2004 | 38 | 0.240 |
Why?
|
| Medical Oncology | 4 | 2019 | 2283 | 0.240 |
Why?
|
| Ultrasonography | 8 | 2022 | 5919 | 0.230 |
Why?
|
| Insulinoma | 1 | 2004 | 121 | 0.230 |
Why?
|
| United States | 20 | 2024 | 71438 | 0.230 |
Why?
|
| T-Lymphocytes | 5 | 2022 | 10035 | 0.230 |
Why?
|
| Appendix | 1 | 2005 | 110 | 0.230 |
Why?
|
| Stomach Ulcer | 1 | 2004 | 123 | 0.230 |
Why?
|
| Carcinoma, Papillary | 2 | 2007 | 782 | 0.230 |
Why?
|
| Thyroid Nodule | 2 | 2002 | 759 | 0.220 |
Why?
|
| Epitopes | 6 | 2012 | 2496 | 0.220 |
Why?
|
| Intestinal Fistula | 1 | 2004 | 142 | 0.220 |
Why?
|
| Gallbladder Diseases | 1 | 2004 | 137 | 0.220 |
Why?
|
| Biopsy, Fine-Needle | 2 | 2018 | 1108 | 0.220 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 1873 | 0.220 |
Why?
|
| Patient Selection | 5 | 2023 | 4239 | 0.220 |
Why?
|
| Abdominal Pain | 3 | 2005 | 1060 | 0.220 |
Why?
|
| Hematoma | 2 | 2005 | 768 | 0.220 |
Why?
|
| Lymphatic Vessels | 2 | 2022 | 354 | 0.220 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2005 | 343 | 0.220 |
Why?
|
| Biological Products | 2 | 2022 | 903 | 0.220 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2004 | 124 | 0.210 |
Why?
|
| Adaptive Immunity | 2 | 2019 | 719 | 0.210 |
Why?
|
| Colonic Diseases | 1 | 2004 | 198 | 0.210 |
Why?
|
| Models, Statistical | 1 | 2017 | 5045 | 0.210 |
Why?
|
| Enoxaparin | 1 | 2005 | 396 | 0.210 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3068 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2024 | 10196 | 0.210 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3187 | 0.210 |
Why?
|
| Genetic Testing | 3 | 2021 | 3506 | 0.200 |
Why?
|
| Myeloblastin | 2 | 2012 | 101 | 0.200 |
Why?
|
| Predictive Value of Tests | 9 | 2021 | 15143 | 0.200 |
Why?
|
| Technetium | 2 | 2019 | 320 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 6 | 2017 | 7400 | 0.200 |
Why?
|
| Melanoma | 4 | 2022 | 5620 | 0.200 |
Why?
|
| Tumor Cells, Cultured | 5 | 2017 | 6137 | 0.200 |
Why?
|
| Pyrazoles | 2 | 2024 | 1984 | 0.200 |
Why?
|
| Gene Expression Regulation | 2 | 2019 | 11884 | 0.200 |
Why?
|
| Tumor Burden | 6 | 2019 | 1875 | 0.190 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2019 | 4279 | 0.190 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2020 | 1114 | 0.190 |
Why?
|
| SOXC Transcription Factors | 1 | 2020 | 41 | 0.190 |
Why?
|
| Accreditation | 1 | 2024 | 464 | 0.190 |
Why?
|
| Adenoma | 3 | 2007 | 2141 | 0.190 |
Why?
|
| Immune Tolerance | 1 | 2010 | 2224 | 0.180 |
Why?
|
| Phthalazines | 2 | 2022 | 376 | 0.180 |
Why?
|
| Premenopause | 3 | 2021 | 1034 | 0.180 |
Why?
|
| Carcinoma in Situ | 2 | 2020 | 794 | 0.180 |
Why?
|
| Postmenopause | 4 | 2024 | 2493 | 0.180 |
Why?
|
| Databases, Factual | 5 | 2019 | 7897 | 0.180 |
Why?
|
| Melanoma, Experimental | 2 | 2021 | 557 | 0.180 |
Why?
|
| Mammaplasty | 3 | 2016 | 1216 | 0.180 |
Why?
|
| Disease Management | 3 | 2019 | 2480 | 0.180 |
Why?
|
| Thyrotoxicosis | 1 | 2001 | 83 | 0.180 |
Why?
|
| Hypersensitivity, Delayed | 3 | 2018 | 480 | 0.180 |
Why?
|
| Camptothecin | 1 | 2023 | 578 | 0.180 |
Why?
|
| Doxorubicin | 2 | 2020 | 2192 | 0.180 |
Why?
|
| Radiopharmaceuticals | 4 | 2023 | 2652 | 0.180 |
Why?
|
| Immunization, Secondary | 2 | 2014 | 357 | 0.180 |
Why?
|
| Lidocaine | 1 | 2023 | 532 | 0.170 |
Why?
|
| Cohort Studies | 13 | 2022 | 40980 | 0.170 |
Why?
|
| Xanthones | 1 | 2019 | 25 | 0.170 |
Why?
|
| Parathyroid Hormone | 2 | 2005 | 1785 | 0.160 |
Why?
|
| Glycosylation | 2 | 2019 | 1086 | 0.160 |
Why?
|
| Nitriles | 1 | 2024 | 955 | 0.160 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2021 | 498 | 0.160 |
Why?
|
| Proportional Hazards Models | 11 | 2018 | 12455 | 0.160 |
Why?
|
| Hormones | 1 | 2022 | 872 | 0.160 |
Why?
|
| Immunophenotyping | 2 | 2024 | 1861 | 0.150 |
Why?
|
| Risk | 6 | 2021 | 9613 | 0.150 |
Why?
|
| Megakaryocytes | 1 | 2022 | 560 | 0.150 |
Why?
|
| Transendothelial and Transepithelial Migration | 1 | 2019 | 103 | 0.150 |
Why?
|
| General Surgery | 3 | 2015 | 1642 | 0.150 |
Why?
|
| Animals | 25 | 2022 | 166811 | 0.150 |
Why?
|
| Tracheostomy | 1 | 2002 | 413 | 0.150 |
Why?
|
| Pyrimidinones | 1 | 2020 | 381 | 0.150 |
Why?
|
| Frail Elderly | 1 | 2023 | 731 | 0.150 |
Why?
|
| Registries | 5 | 2022 | 8367 | 0.150 |
Why?
|
| Multivariate Analysis | 6 | 2018 | 12138 | 0.150 |
Why?
|
| Carcinoma | 2 | 2010 | 2340 | 0.150 |
Why?
|
| Mucin-1 | 2 | 2012 | 548 | 0.150 |
Why?
|
| Medicare | 3 | 2024 | 6686 | 0.150 |
Why?
|
| Ferric Compounds | 1 | 2019 | 376 | 0.140 |
Why?
|
| Interferons | 2 | 2019 | 700 | 0.140 |
Why?
|
| Vertebral Artery | 1 | 1998 | 186 | 0.140 |
Why?
|
| Neuropilin-1 | 1 | 2017 | 90 | 0.140 |
Why?
|
| Life Expectancy | 1 | 2024 | 1243 | 0.140 |
Why?
|
| Vaccines, Attenuated | 1 | 2018 | 312 | 0.140 |
Why?
|
| Mice | 16 | 2022 | 80550 | 0.140 |
Why?
|
| Anthracyclines | 3 | 2023 | 282 | 0.140 |
Why?
|
| Immune System | 1 | 2022 | 796 | 0.140 |
Why?
|
| Skin Neoplasms | 4 | 2012 | 5726 | 0.140 |
Why?
|
| Aromatase Inhibitors | 1 | 2020 | 510 | 0.130 |
Why?
|
| Immunoconjugates | 1 | 2023 | 865 | 0.130 |
Why?
|
| Nanomedicine | 1 | 2019 | 292 | 0.130 |
Why?
|
| Integrins | 1 | 2020 | 840 | 0.130 |
Why?
|
| Benchmarking | 1 | 2022 | 1036 | 0.130 |
Why?
|
| ROC Curve | 3 | 2019 | 3532 | 0.130 |
Why?
|
| Mediastinal Neoplasms | 1 | 2019 | 401 | 0.130 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2019 | 661 | 0.130 |
Why?
|
| Parathyroid Glands | 2 | 2008 | 519 | 0.130 |
Why?
|
| Feasibility Studies | 6 | 2018 | 5148 | 0.130 |
Why?
|
| Chromium | 2 | 2006 | 132 | 0.130 |
Why?
|
| Tissue Distribution | 2 | 2019 | 2285 | 0.130 |
Why?
|
| Mutation | 9 | 2024 | 29706 | 0.130 |
Why?
|
| Double-Blind Method | 2 | 2020 | 12328 | 0.130 |
Why?
|
| Incidence | 9 | 2018 | 21157 | 0.130 |
Why?
|
| Glypicans | 1 | 2015 | 34 | 0.130 |
Why?
|
| International Agencies | 1 | 2016 | 244 | 0.130 |
Why?
|
| Hypoparathyroidism | 2 | 2008 | 133 | 0.120 |
Why?
|
| Multigene Family | 1 | 2018 | 1075 | 0.120 |
Why?
|
| NF-kappa B | 1 | 2023 | 2471 | 0.120 |
Why?
|
| Antigens, CD | 1 | 2005 | 3908 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 3 | 2021 | 6112 | 0.120 |
Why?
|
| Monocytes | 1 | 2024 | 2556 | 0.120 |
Why?
|
| Cisplatin | 1 | 2020 | 1643 | 0.120 |
Why?
|
| Bone Neoplasms | 3 | 2019 | 2511 | 0.120 |
Why?
|
| Intraoperative Care | 1 | 2018 | 759 | 0.120 |
Why?
|
| Education, Medical, Continuing | 2 | 2015 | 829 | 0.120 |
Why?
|
| Clinical Competence | 2 | 2015 | 4715 | 0.120 |
Why?
|
| Risk Factors | 14 | 2022 | 73425 | 0.120 |
Why?
|
| Radiation Oncology | 1 | 2020 | 560 | 0.110 |
Why?
|
| California | 1 | 2018 | 1396 | 0.110 |
Why?
|
| Enteral Nutrition | 1 | 1999 | 777 | 0.110 |
Why?
|
| Bone Marrow | 1 | 2024 | 2902 | 0.110 |
Why?
|
| Surgical Instruments | 3 | 2022 | 386 | 0.110 |
Why?
|
| Respiratory Insufficiency | 1 | 2002 | 1209 | 0.110 |
Why?
|
| Point-of-Care Systems | 1 | 2002 | 1183 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2017 | 20351 | 0.110 |
Why?
|
| Data Collection | 1 | 2022 | 3301 | 0.110 |
Why?
|
| Kidney Diseases | 1 | 2004 | 2056 | 0.110 |
Why?
|
| Cerebral Infarction | 1 | 1998 | 980 | 0.110 |
Why?
|
| Extremities | 1 | 2018 | 854 | 0.110 |
Why?
|
| Signal Transduction | 7 | 2021 | 23234 | 0.110 |
Why?
|
| Survival | 1 | 2013 | 161 | 0.110 |
Why?
|
| Hepatitis C | 1 | 2023 | 1573 | 0.110 |
Why?
|
| Brain Stem | 1 | 1998 | 851 | 0.100 |
Why?
|
| Reproducibility of Results | 4 | 2018 | 19901 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 1708 | 0.100 |
Why?
|
| Social Class | 1 | 2021 | 1992 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2024 | 2868 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 2018 | 958 | 0.100 |
Why?
|
| Carboplatin | 3 | 2022 | 788 | 0.100 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2016 | 587 | 0.100 |
Why?
|
| Cell Proliferation | 3 | 2017 | 10360 | 0.100 |
Why?
|
| Ki-67 Antigen | 2 | 2023 | 631 | 0.100 |
Why?
|
| Wounds, Gunshot | 1 | 1998 | 578 | 0.100 |
Why?
|
| Nanotechnology | 1 | 2017 | 704 | 0.100 |
Why?
|
| Thoracic Wall | 1 | 2013 | 199 | 0.100 |
Why?
|
| Adolescent | 11 | 2020 | 86766 | 0.100 |
Why?
|
| Endoscopy | 1 | 2001 | 1838 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2024 | 2979 | 0.100 |
Why?
|
| Glycomics | 1 | 2012 | 109 | 0.100 |
Why?
|
| Laparoscopy | 1 | 2003 | 2134 | 0.100 |
Why?
|
| Intensive Care Units | 2 | 2002 | 3697 | 0.100 |
Why?
|
| Thoracic Neoplasms | 1 | 2013 | 267 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2021 | 5164 | 0.100 |
Why?
|
| Male | 21 | 2022 | 354908 | 0.100 |
Why?
|
| Academic Medical Centers | 2 | 2023 | 2715 | 0.100 |
Why?
|
| Certification | 1 | 2015 | 420 | 0.090 |
Why?
|
| Glycopeptides | 1 | 2012 | 220 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2020 | 3554 | 0.090 |
Why?
|
|